Lisa Madden

Professor contributing to global discussions on innovative treatments in pediatric hematology and oncology, Dr. Lisa Madden is an esteemed Associate Professor in the Department of Pediatrics at UC Davis Health. With a specialization in Pediatric Hematology/Oncology and Stem Cell Transplant, Dr. Madden is dedicated to advancing care for children and young adults facing a range of malignant and non-malignant hematological disorders. Dr. Madden's clinical expertise is particularly focused on stem cell transplant and cellular therapies, with a keen interest in addressing hemoglobinopathies such as sickle cell disease and thalassemia. Her commitment to improving patient outcomes is evident in her pursuit of optimizing curative options for these conditions. She is actively engaged in research that explores the potential of gene editing technologies to offer new hope for patients with these challenging disorders. In addition to her work on gene editing, Dr. Madden is deeply involved in research aimed at enhancing the graft versus malignancy effects in allogeneic transplants. Her innovative approach seeks to maximize the therapeutic benefits of transplants while minimizing associated risks. This includes developing novel strategies to address and treat transplant-related complications, ensuring that patients receive the most effective and safe care possible. Dr. Madden's contributions to the field extend beyond her clinical and research endeavors. She is a respected voice in the scientific community, frequently participating in discussions and collaborations that aim to push the boundaries of current medical knowledge and practice. Her work not only impacts her patients directly but also influences broader treatment protocols and strategies in pediatric hematology and oncology. Through her dedication to both patient care and research, Dr. Madden exemplifies the integration of clinical practice with scientific inquiry. Her efforts continue to pave the way for advancements in the treatment of hemoglobinopathies and other hematological disorders, offering hope and improved quality of life for countless children and young adults.